TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Myfortic Versus Azathioprine in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged 18 years and over~* Patients meeting the diagnostic criteria for SLE (Appendix 2), according to ACR guidelines (including screening for anti-dsDNA (antibody to native DNA in abnormal titer))~* SLEDAI \> 6~* Patients treated with maintenance therapy including azathioprine.~* Patients who are willing and able to participate in the study and from whom written informed consent has been obtained~Exclusion Criteria:~* Creatinine clearance of \< 20ml/min~* Patients with any clinically significant infection~* Patients with known hypersensitivity to myfortic ® or to drugs with similar chemical structures~* Patients with a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin~* Patients with SLE active CNS manifestations or a past history of SLE CNS complications (e.g. psychosis, grand mal seizures)~* Patients who have received prior therapy with mycophenolic acids (MPAs) (e.g. MMF)~* Patients who have received an investigational drug within four weeks prior to study entry~* Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* must be of legal age and competent~* Age \> 18 years~* presently diagnosed with hypothyroidism~Exclusion Criteria:~* alcohol consumption \>21 units per week~* Malignant disease~* pregnancy~* magnetic implants or material in the body~* BMI \> 30~* Heart disease (NYHA \>2)~* Uncontrolled hypertension~* Manifest diabetes mellitus~* Changes in medication, with any influence on glucose metabolism, 2 months prior to and until the end of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of trial SP889~Exclusion Criteria:~* Ongoing serious adverse event assessed as related to trial medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): Rotigotine Transdermal Patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 8- 18 years 2) Patients undergoing minimally invasive pectus excavatum repair via Nuss procedure 3) American Society of Anesthesiology Status I-III~Exclusion Criteria:~* 1) Refusal of epidural catheter 2) Pregnancy 3) Bleeding History 4) Inability to understand how to use the PCA device 5) Medication interfering with blood coagulation 6) Patients allergic to local anesthetics 7) Patient refusal to participate in study 8) Developmental delay

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Patient Controlled Analgesia (Type: ACTIVE_COMPARATOR): One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
- epidural Catheter (Type: ACTIVE_COMPARATOR): The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Desarda and Lichtenstein Techniques in Inguinal Hernia Treatment.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary inguinal hernia~* male adults~* signed informed consent~* god condition of external oblique aponeurosis (assessed during the operation)~Exclusion Criteria:~* age \< 18~* recurrent hernia~* incarcerated hernia~* diagnosed mental disorder~* manual reduction of hernia on inpatient~* infection at groin area~* wound or scar at the groin~* no consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desarda group (Type: EXPERIMENTAL): Patients with primary inguinal hernia operated using the Desarda technique
- Lichtenstein group (Type: EXPERIMENTAL): Patients with primary inguinal hernia operated using the Lichtenstein technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of adenocarcinoma of the prostate.~* evidence of metastatic disease within 4 weeks of registration.~* Must meet ONE of the following:~  1. PSA \>or= 10 ng/mL and at least one lesion on bone scan.~ 2. Soft tissue metastases and/or visceral disease per CT scan.~* Must show progressing prostate cancer as seen by one of the following:~  1. At least one new lesion on bone scan,~ 2. Increase in size or number of measurable disease lesions,~ 3. At least 2 rising PSA measurements at least two weeks apart.~* Prior bilateral orchiectomy or on LHRH agonist therapy with a serum testosterone level of \< 50.~* Must be off flutamide, nilutamide, or ketoconazole or herbal supplements used to treat prostate cancer at least 4 weeks prior to registration and bicalutamide at least 6 weeks prior to registration.~* No prior cytotoxic chemotherapy.~* WHO performance status of 0-2.~* Peripheral neuropathy must be \< or = to grade 1.~Exclusion Criteria:~* A history of a radiographically confirmed kidney stone or pathologically confirmed calcium stone within the last 10 years.~* Patients can continue to take bisphosphonates during the study as long as the bisphosphonate was started at least 4 weeks prior to study entry and the patient continues to demonstrate a rising PSA~* No prior treatment with suramin, strontium or other therapeutic radioisotopes.~* No radiotherapy within the past 4 weeks.~* No known brain metastases.~* No chronic hypercalcemia (serum calcium \>1.0 mg/dl above the upper limit of normal range), chronic gastrointestinal disease (malabsorption, surgery affecting absorption, chronic ulcerative colitis) or any condition that the investigator feels would put the patient at undue risk.~* Must not be taking digitalis, thiazide diuretics (or drugs in combination with thiazides) or calcium supplements within one week of treatment initiation.~* No active angina, known heart disease of New York Heart Association Class II-IV or a recent history (\< 6 months) of myocardial infarction.~* Must not be taking steroids, anticonvulsants, fluoride, or lithium.~* Must not have urinary protein \> 4gm/24 hours~* Must not have urinary calcium \> or= 500 mg/24 hours~* No Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin that has been treated curatively).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Docetaxel plus doxercalciferol
- B (Type: PLACEBO_COMPARATOR): Docetaxel plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with DMD~* Able to walk without assistance~* Able to walk up 4 stairs in 8 seconds or less~* Weigh at least 15 kg~* Taking corticosteroids for DMD~Exclusion Criteria:~* Ejection fraction \< 55% on echocardiogram, based on central read~* Any behavior or mental issue that will affect the ability to complete the required study procedures~* Previously or currently taking medications like androgens or human growth hormone~* Use of a ventilator during the day~* Unable to have blood samples collected or receive an injection under the skin~* Treatment with exon skipping therapies 6 months prior to study start~* Treatment with ataluren or any investigational drug currently or within 5 half-lives prior to study start

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- RO7239361 (Type: ACTIVE_COMPARATOR): RO7239361 subcutaneous injections on specified days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injections on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Mitral Regurgitation Using a Minimally Invasive Approach With the HARPOON Device.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is \> 18 years old~2. Presence of severe MR as read on a transthoracic echocardiographic study~3. Mitral leaflet coaptation surface is sufficient to reduce mitral regurgitation without undue leaflet tension (approximate leaflet to gap ratio of 2:1) based on the judgment of the patient eligibility committee and the operating surgeon~4. Degenerative mitral valve disease with mid-segment P2 prolapse~5. Patient is able to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation~Exclusion Criteria:~1. Patient is of the age where further growth is expected~2. Active endocarditis~3. Left ventricular or left atrial appendage thrombus~4. Severe mitral annular and/or leaflet calcification~5. Cannot tolerate procedural anticoagulation or post-procedure antiplatelet regimen~6. Mitral stenosis~7. Functional Mitral Valve disease~8. Previous mitral valve replacement surgery~9. Fragile or thinning apex~10. Contraindications to transoesophageal echocardiography (atlantoaxial disease, severe generalized cervical arthritis, upper gastrointestinal bleeding, significant dysphagia and odynophagia, has received extensive radiation to the mediastinum)~11. Patient is pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HARPOON MVRS (Type: OTHER): Subjects who were treated with the HARPOON MVRS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Diagnostic Advantages of Tilt Down Verses Standard Horizontal Colonoscopy Positioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ability to understand and sign consent~* women and men with a BMI (body mass index) \<35 kg/m2~* age 18 - 90 years~* no liquids by mouth for ≥2 hours~* no solid food for ≥8 hours~Exclusion Criteria:~* inability to provide informed consent~* morbid obesity (BMI ≥35)~* pregnancy~* uncontrolled gastroesophageal reflux disease~* gastroparesis~* scleroderma~* achalasia~* Crohn's disease~* ulcerative colitis~* history of a colon resection~* Parkinson's disease~* brain tumor~* multiple sclerosis~* ischemic optic neuropathy~* glaucoma~* active pulmonary infection~* liquid intake \<2 hours~* solid food intake \<8 hours prior to the procedure~* intra-procedure findings of a stricture resulting in an incomplete colonoscopy or Boston bowel preparation scores of \<6

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Lateral horizontal body position (Type: OTHER): Subjects randomized to receive colonoscopy in the lateral horizontal position, This is the standard position. The other position - tilt down is the intervention
- Lateral tilt down body position (Type: OTHER): Subjects randomized to receive colonoscopy in the lateral tilt down position

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Measurable disease with diagnosis of Small Cell Lung Cancer.~* Performance status of 0 to 1 on the Eastern Cooperative Oncology Group performance status schedule.~* Patients must be at least 18 years of age and have at least a 12-week life expectancy.~* No prior chemotherapy and/or prior thoracic radiotherapy.~* Adequate pulmonary function and organ function.~Exclusion Criteria:~* Patients with myocardial infarction within the preceding six months.~* Diagnosis of a serious concomitant systemic disorder.~* Prior radiotherapy to the lower neck or abdominal region.~* Significant weight loss.~* Concurrent administration of any other antitumor therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ProStat Supplementation in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On hemodialysis~* Optimally dialyzed with a biocompatible membrane (URR \> 70% and/or delivered Kt/V \>1.2)~* Patient or next of kin able to sign consent form~* Average of Serum Albumin for the consecutive two months prior to inclusion \</= 3.7 g/dl and the serum albumin for the previous month is \< 3.7 mg/dl.~* Sub-optimal nutritional status identified by one of the four following criteria:~  1. Protein catabolic rate less than 1.0 g/kg/d on at least 2 occasions over the past 6 months~ 2. Progressive unintentional weight loss more than 2.5% of the initial or ideal body weight and/or patients who are less than 90% of Standard Body Weight~ 3. Subjective Global Assessment Score consistent with Moderate to Severe Malnutrition within the last month~ 4. Biochemical parameters of malnutrition defined by 1 of 2 of the following measurements (if available) over the consecutive two months prior to inclusion:~     1. Serum transferrin concentration less than 225 mg/dl~    2. Serum prealbumin concentration less than 32 mg/dl~* Patient is able to transfer with minimal or no assistance.~* Not taking a caloric nutritional supplement for the last 30 days (e.g. Nepro, ProStat, Boost,etc).~Exclusion Criteria:~* Active auto-immune, inflammatory or infectious disease~* Documented malignancy within the last 12 months~* Patients on unusual dietary restrictions~* Life-expectancy less than 6 months~* Inability to tolerate nutritional supplements~* Patient does not exceed the DEXA machine weight limit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
- B (Type: PLACEBO_COMPARATOR): Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Stage IV Lung Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed lung adenocarcinoma.~2. Stage IV disease as defined by AJCC 7th edition staging.~3. At least one measurable lesion (as defined by RECIST v1.1).~4. No prior radiotherapy, chemotherapy, surgery, target therapy, or immunotherapy for NSCLC. (Except the surgery for biopsy or port-A implantation, palliative localized radiotherapy for bone metastasis).~5. Age ≤ 80 years old and ≥ 20 years old.~6. ECOG performance status of 0-2.~7. Adequate organ function, including followings~   Bone marrow:~   Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L; WBC ≥ 3.0 x 10\^9/L Platelet count ≥ 100 x 10\^9/L Hemoglobin ≥ 9g/dL~   Hepatic:~   Total bilirubin level ≤ 1.0 x UNL AST and ALT ≤ 3.0 x UNL;~   Renal:~   Creatinine level ≤ 1.5 mg/dL in men, ≤1.4 mg/dL in women; or Estimated CCr ≥ 60 mL/min. (CCr is estimated by Cockcroft-Gault formula, as appendix II)(CCr is estimated by Cockcroft-Gault formula)~8. Estimated life expectancy of at least 6 months.~9. Written (signed) Informed Consent.~Exclusion Criteria:~1. With other primary malignancies, except those remain disease-free for 3 or more years after curative treatment, basal cell cancer of the skin or in situ cervical cancer.~2. Use of other anti-cancer therapy, including chemotherapy, target therapy, immunotherapy, radiotherapy, and hormone therapy.~3. Prior participation in any investigational drug study within 28 days.~4. Use of anti-IL-6 or IL-6-lowering agents.~5. Use of metformin in the past 6 months.~6. Poor controlled diabetes (HbA1c ≥ 8.0%).~7. Known hypersensitivity or intolerance to metformin.~8. Congestive heart failure with NYHA functional class II\~IV.~9. History of lactic acidosis.~10. Significant concurrent medical diseases, such as unstable angina, acute or recent myocardial infarction (\< 6 months before enrollment), COPD with frequent exacerbation, uncontrolled hypertension, or recent CVA (\< 6 months before enrollment).~11. Active uncontrolled infections or HIV infection.~12. Psychiatric disorders that would compromise the patient's compliance or decision.~13. Current or planned pregnancy, or breast feeding in women.~14. Poor compliance.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- METFORMIN (Type: EXPERIMENTAL): For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues